Isolating Lung Progenitor Cells via CD47hi CD26lo FACS Sorting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for isolating lung progenitor cells from adult human lungs are challenging, and existing approaches, such as reprogramming autologous cells to induced pluripotent stem cells, face difficulties in efficient differentiation and rejection prevention.
Innovation Solution
The method involves isolating lung progenitor cells based on the expression of specific cell surface markers CD47hi and CD26lo, using differentiation-inducing agents like CHIR 99021, BMP4, KGF, FGF10, and retinoic acid, and employing fluorescence-activated cell sorting (FACS) to achieve high purity and standardization.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If lung progenitor cells are isolated from adult human lung, then endogenous lung cells can be regenerated, but isolation is difficult and time-consuming
Solution Approach 1:
The patent applies preliminary action by reprogramming autologous cells to induced pluripotent stem cells (iPSCs) before differentiation. This preliminary reprogramming step enables subsequent efficient differentiation into lung progenitor cells, avoiding the time-consuming direct isolation from adult lung tissue.
Solution Approach 2:
Instead of directly isolating lung progenitor cells from adult lung tissue (forward approach), the patent inverts the approach by first reprogramming somatic cells to iPSCs and then differentiating them into lung progenitor cells (reverse approach), achieving both efficiency and high purity.
2Reliability
If autologous cells are reprogrammed to induced pluripotent stem cells, then rejection can be prevented, but differentiation efficiency is low
Solution Approach 1:
The patent applies parameter changes by optimizing differentiation conditions including specific growth factors (FGF10, KGF, BMP4), small molecules (CHIR99021, retinoic acid), and culture parameters to achieve high differentiation efficiency while maintaining the autologous nature of cells for rejection prevention.
Solution Approach 2:
The patent uses intermediaries in the form of specific differentiation-inducing agents (growth factors, small molecules) that mediate the transformation from iPSCs to lung progenitor cells, enabling efficient and controlled differentiation while preserving immune compatibility.
3Manufacturing precision
If cell surface markers are used for isolation, then purity can be increased, but complexity of the method increases
Solution Approach 1:
The patent applies color changes principle through fluorescence-activated cell sorting (FACS) which uses fluorescently labeled antibodies to detect and sort cells based on cell surface marker expression, achieving high purity through optical detection and sorting.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for the efficient and standardized isolation of lung progenitor cells, enabling their use in regenerative therapies by avoiding rejection and ensuring high purity, thus potentially treating lung diseases effectively.
Implementation Method 1
contacting a pluripotent stem cell population with at least one differentiation-inducing agent, and sorting one or more cells having high expression of CD47 (CD47hi) from the pluripotent stem cell population, thereby isolating one or more lung progenitor cells
Implementation Method 2
employing fluorescence-activated cell sorting (FACS) to achieve high purity and standardization
Data Source
AI summary
Provided herein are methods and compositions relating, in part, to the generation and isolation of human lung progenitor cells from pluripotent stem cells.